Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAD-1: Toxicity-Adjusted vs Fixed-Dose Cisplatin and Etoposide in SCLC
NCT00526396Phase 3Unknown
- Sponsor
- National Cancer Institute
- Start
- Sep 2007
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cisplatin, etoposide in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Status: unknown.
02
Drugs
cisplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00526396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00526396.